Abstract
Sucampo Pharmaceuticals Inc and Takeda Pharmaceutical Co Ltd are developing, a ClC-2 chloride channel activator and a bicyclic member of a series of fatty acid compounds, for the potential treatment of a number of gastrointestinal conditions, including constipation, irritable bowel syndrome, postoperative bowel dysfunction and opioid bowel dysfunction.
| Original language | English |
|---|---|
| Pages (from-to) | 416-22 |
| Number of pages | 7 |
| Journal | IDrugs : the investigational drugs journal |
| Volume | 8 |
| Issue number | 5 |
| Publication status | Published - May 2005 |
Keywords
- Alprostadil/adverse effects
- Constipation/drug therapy
- Diarrhea/chemically induced
- Fatty Acids/therapeutic use
- Headache/chemically induced
- Humans
- Lubiprostone
- Nausea/chemically induced
- Randomized Controlled Trials as Topic
